Nintedanib Accord Healthcare

Nintedanib, the active ingredient in Nintedanib Accord Healthcare, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is indicated for certain fibrotic lung disorders and for use in combination therapy for a type of lung cancer. GNH USA supplies Nintedanib Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nintedanib acts on multiple receptor tyrosine kinases involved in fibrotic remodeling and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows the decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: helps preserve vital capacity and delay worsening of respiratory symptoms. - Non‑small cell lung cancer (in combination therapy): contributes to tumour control when used with standard chemotherapy regimens.

Nintedanib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhoea: frequent, often mild to moderate in intensity. - Nausea: may occur with or without vomiting. - Vomiting: occasional, usually self‑limiting. - Abdominal pain: mild discomfort reported by some patients. - Decreased appetite: reduced food intake leading to possible weight loss. - Elevated liver enzymes: mild transaminase increases.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe infections: opportunistic infections in immunocompromised individuals. - Gastrointestinal perforation: rare but potentially life‑threatening. - Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters. - Liver function monitoring: check transaminases and bilirubin before treatment and periodically thereafter. - Bleeding risk assessment: avoid concurrent use with strong anticoagulants unless benefits outweigh risks. - Cardiovascular evaluation: consider baseline cardiac status in patients with known disease. - Pregnancy and lactation: use only if potential benefit justifies potential risk; safety data are limited. - Hepatic impairment dosing: adjust dose in moderate to severe liver dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nintedanib may interact with other medicines that affect its metabolism or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nintedanib exposure. - Potent P‑gp inhibitors (e.g., verapamil): can increase plasma concentrations. - Anticoagulants and antiplatelet agents (e.g., warfarin, clopidogrel): heightened bleeding potential.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - P‑gp inducers (e.g., phenytoin): could lower drug exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for additive gastrointestinal bleeding risk.